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Abstract
Background: Effects of hypobaric hypoxia at altitude on ex-
ercise performance of lowlanders with chronic obstructive 
pulmonary disease (COPD) have not been studied in detail. 
Objectives: To quantify changes in exercise performance 
and associated physiologic responses in lowlanders with 
COPD travelling to moderate altitude. Methods: A total of 
31 COPD patients with a median age (quartiles) of 66 years 
(59; 69) and FEV1 of 56% predicted (49; 69) living below 800 
m performed a constant-load bicycle exercise to exhaustion 
at 60% of the maximal work rate at 490 m (Zurich) and at an 
identical work rate at 2,590 m (Davos) in randomized order. 
Pulmonary gas exchange, pulse oximetry (SpO2), cerebral 
tissue oxygenation (CTO; near-infrared spectroscopy), and 
middle cerebral artery peak blood flow velocity (MCAv) by 
Doppler ultrasound during 30 s at end exercise were com-
pared between altitudes. Results: With ascent from 490 to 
2,590 m, the median endurance time (quartiles) was re-
duced from 500 s (256; 795) to 205 s (139; 297) by a median 
(95% CI) of 303 s (150–420) (p < 0.001). End exercise SpO2 
decreased from 92% (89; 94) to 81% (77; 84) and CTO from 
62% (56; 66) to 55% (50; 60); end exercise minute ventilation 
increased from 40.6 L/min (35.5; 47.8) to 47.2 L/min (39.6; 
58.7) (p < 0.05; all comparisons 2,590 vs. 490 m). MCAv in-
creased similarly from rest to end exercise at 490 m (+25% 
[17; 36]) and at 2,590 m (+21% [14; 30]). However, the ratio 
of MCAv increase to SpO2 drop during exercise decreased 
from +6%/% (3; 12) at 490 m to +3%/% (2; 5) at 2,590 m (p < 
0.05). Conclusions: In lowlanders with COPD travelling to 
2,590 m, exercise endurance is reduced by more than half 
compared to 490 m in association with reductions in sys-
temic and cerebral oxygen availability.
© 2018 S. Karger AG, Basel
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Introduction
Worldwide, millions of persons travel to high altitude 
for professional or recreational activities and this is gen-
erally well tolerated by healthy individuals. In turn, pa-
tients with a preexisting lung disease such as chronic ob-
structive pulmonary disease (COPD) may experience a 
pronounced exercise limitation at altitude that restricts 
their daily activities. Near sea level, exercise performance 
of COPD patients is impaired by dyspnea [1], gas ex-
change and ventilatory limitations with dynamic hyper-
inflation [2, 3], muscle weakness [4, 5], and several other 
factors [6]. The reduced inspiratory pressure of O2 at 
higher altitude may aggravate the impairment of exercise 
performance by inducing hypoxemia and pulmonary 
vasoconstriction. Further, mechanical ventilatory con-
straints that impair the response to hypoxemia may com-
bine with additional factors limiting exercise perfor-
mance, such as cerebral hypoxia, as suggested by studies 
on healthy subjects [7–9].
In COPD patients, the physiologic effects of altitude 
exposure have not been studied in detail. Therefore, the 
purpose of the current study was to quantify the changes 
in exercise performance in lowlanders with COPD as-
cending from 490 to 2,590 m and to test the hypothesis 
that altitude-induced changes in exercise performance 
are associated with changes in systemic and cerebral 
availability of oxygen.
Methods
Design
The current data were collected from June to August 2013 from 
participants in a randomized trial evaluating adverse effects of al-
titude exposure in COPD patients travelling from 490 to 2,590 m 
(ClinicalTrial.gov NCT01875133). The patient characteristics 
were previously reported in abstract form [10, 11]. The data on 
cardiopulmonary exercise and cerebral blood flow presented here 
have not been published yet.
Participants
Patients with COPD diagnosed according to the GOLD criteria 
with severity grades of 2–3 (FEV1/FVC < 0.7 and FEV1 30–80% 
predicted), aged 18–75 years (both genders), and residing below 
800 m were invited to participate. Exclusion criteria were a resting 
SpO2 < 92% at 490 m or < 80% at 2,590 m right before exercise, any 
acute intercurrent disease or inadequately controlled cardiovascu-
lar disease, and a history of previous stroke or obstructive sleep 
apnea. Informed written consent was obtained, and the study was 
approved by the institutional ethics committee of the canton of 
Zurich, Switzerland (EK-2013-0088).
Interventions
The participants spent 2 days each at 490, 1,650, and 2,590 m 
(mean barometric pressures [PB] of 720, 626, and 562 mm Hg, re-
spectively). According to the rationale of the main trial, the patients 
were randomized to one of the following 4 different altitude expo-
sure sequences: (A) 490-1,650-2,590 m; (B) 490-2,590-1,650 m; (C) 
1,650-2,590-490 m; and (D) 2,590-1,650-490 m. Due to logistic rea-
sons, the assessments for the current study could only be per-
formed at 490 and 2,590 m. The measurements at 490 m and at the 
higher altitudes were scheduled 2 weeks apart to let patients re-
cover completely and to allow for washout of any effects of accli-
matization. Transfers between locations were made by train (from 
Zurich to Davos) and cable car (1,650–2,590 m) within 2–5 h.
On the second day, after the first night at 490 and 2,590 m, be-
tween 14: 00 and 17: 00, the patients performed a cycling exercise 
to exhaustion in a semi-recumbent position (60° head-up; ergoline 
GmbH, Bitz, Germany). At 490 and 2,590 m, individually identical 
constant-load protocols were applied with a mean load ± SD of 
65 ± 29 W, corresponding to 60% of the maximal work rate as-
sessed by the ramp protocol at 490 m. Baseline measurements were 
obtained during 5 min at rest on the bicycle. The patients then 
started cycling at 60 rpm and were encouraged to continue as long 
as possible. End exercise was defined as a reduction in cycling fre-
quency to < 40 rpm.
Measurements
Work rates and breath-by-breath pulmonary gas exchange 
measures were recorded by a metabolic unit (Ergostick; Gera-
therm Medical AG, Geschwenda, Germany) according to standard 
techniques [12]. According to convention, minute ventilation 
(V′E) and tidal volume (VT) were expressed in BTPS (body tem-
perature and pressure, saturated) conditions, and oxygen uptake 
(V′O2) and carbon dioxide output (V′CO2) in STPD (standard tem-
perature and pressure, dry) conditions. To adjust for the increase 
in V′E (measured in BTPS) related to the lower PB at 2,590 m, 
values of ventilatory equivalents adjusted to the PB at 490 m 
were computed so that the molecular gas flow corresponded to that 
at 490 m, i.e., V′E/V′CO2 adj. = [V′E2,590m × (PB2,590m – PH2O)/ 
(PB490m – PH2O)]/V′CO2. Breathing reserve was computed as 40 × 
FEV1 – V′E at end exercise, and the dead-space-to-VT ratio as VD/
VT = [(PaCO2 – PetCO2)/PaCO2] [12]. Breath-by-breath changes in 
end-expiratory lung volume (EELV) were monitored unobtrusive-
ly by calibrated respiratory inductive plethysmography operated 
in the direct current mode (Respitrace; NIMS, Miami Beach, FL, 
USA) [13, 14]. The intention was to avoid potential alterations in 
the natural breathing pattern by repeated inspiratory-capacity ma-
neuvers. Operating lung volumes were calculated as follows: func-
tional residual capacity (FRC) at rest was measured by body pleth-
ysmography (see below); EELV over the course of exercise was 
calculated as FRC + change in EELV over the course of exercise; 
end-inspiratory lung volume (EILV) was calculated as EELV + 
tidal volume; inspiratory reserve volume (IRV) was calculated as 
TLC – EILV. SpO2, electrocardiograms, blood pressure, near- 
infrared spectroscopy (NIRS) images of the frontal brain and 
quadriceps muscles, and blood flow velocity in the middle cerebral 
artery (MCA) by transcranial Doppler ultrasound were continu-
ously recorded.
NIRS optodes (NIRO-200NX, Hamamatsu, Japan) were 
placed bilaterally at the Fp1 and Fp2 landmarks of the 10-10 elec-
trode placement system [15] and bilaterally over the vastus late-
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ralis muscles [16]. Mean values of bilateral cerebral (CTO) and 
bilateral quadriceps muscle (MTO) tissue oxygenation, calculated 
as the ratio of the oxygenated/oxygenated + deoxygenated hemo-
globin concentration, are reported. A 2-MHz ultrasound Doppler 
probe (TOC2M; Multigon Industries, New York, NY, USA) was 
placed over the temporal window to record the right MCA peak 
blood flow velocity (MCAv) [17]. The cerebral blood flow re-
sponse to the exercise-induced change in SpO2 was quantified by 
calculating the ratio of change in MCAv per change in SpO2. Con-
tinuous blood pressure recordings were obtained by the finger 
cuff technique (Finometer Midi; Finapres Medical Systems, Am-
sterdam, The Netherlands). At both altitudes, arterial blood sam-
ples were drawn during a resting period before exercise and dur-
ing the final 30 s of end exercise. Spirometry, body plethysmogra-
phy, and measurement of single breath diffusing capacity were 
performed according to standard techniques with the reference 
values of the Global Lung Function Initiative (GLI) and Quanjer 
et al. [18–22]. Dyspnea and leg fatigue were rated on the Borg 
CR10 Scale [23].
Outcomes
The main outcome of this study was the change in cycling en-
durance between measurements at 490 and 2,590 m. Additional 
outcomes were changes in physiologic variables.
Data Analysis
The data are summarized as medians and quartiles. Analyses 
were performed according to the per-protocol approach including 
data from patients with complete data. Median values of physiolog-
ic variables measured during 3 min of quiet rest, during the final 30 
s of end exercise, and during the time (isotime) corresponding to the 
end exercise time in tests with shorter endurance were computed. 
Paired comparisons were performed by Wilcoxon signed-rank tests 
and by computing median differences with 95% confidence intervals 
(CI). Multivariate regression analysis was performed to elucidate 
whether the order of altitude exposure, baseline endurance, or other 
baseline variables were independent predictors of exercise endur-
ance at 2,590 m. The outcome assessors were blinded to altitude al-
location. A probability < 0.05 was considered statistically significant.
191 patients were assessed for
eligibility
1 technical failure
1 withdrew consent
40 underwent randomization
Assessments at 490 m
n = 21
Travel to altitude
Assessments at 2,590 m
n = 19
Assessments at 490 m
n = 14
Travel to altitude
Assessments at 2,590 m
n = 19
2 SpO2 <80% before exercise
1 withdrew consent
1 SpO2 <80% before exercise 1 withdrew consent
151 were not eligible:
– 139 declined to participate
– 12 had relevant comorbidities
2-week washout period
at <800 m
18 included in
per-protocol analysis
13 included in
per-protocol analysis
2-week washout period
at <800 m 2 withdrew consent
Fig. 1. Patient selection flowchart of the study.
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Results
The patient selection flowchart is shown in Figure 1. 
From 40 randomized patients, 9 data sets had to be ex-
cluded, leaving 31 for the per-protocol analysis. No seri-
ous adverse events occurred, although 3 patients had an 
SpO2 < 80% before starting exercise and were therefore 
excluded from these tests. The patient characteristics are 
summarized in Table 1.
Table 1. Patient characteristics
General information
Subjects (male/female), n 31 (19/12)
Age, years 66 (59; 69)
Range 51–74
Body mass index 27.3 (22.0; 29.4)
Smoking habit
Current 7
Former 22
Never 2
Smoking, pack-years 40 (20; 60)
Pulmonary function and oxygen uptake at 490 m at 2,590 m
FVC, L 3.36 (2.63; 4.01) 3.30 (2.87; 4.07)
FVC, % predicted 88 (77; 100) 92 (77; 101)
FEV1, L 1.69 (1.28; 2.14) 1.76 (1.33; 2.17)
FEV1, % predicted 56 (49; 69) 53 (48; 66)
FEV1/FVC, % 52 (46; 63) 55 (46; 64)
FEV1/FVC, % predicted 66 (58; 80) 70 (57; 81)
TLC, L 6.79 (5.77; 7.79)
TLC, % predicted 111 (97; 118)
RV, L 2.94 (2.55; 3.39)
RV, % predicted 127 (118; 140)
RV/TLC, % 45 (40; 50)
FRC, L 4.36 (3.62; 5.14)
FRC, % predicted 135 (125; 153)
DLCO, mmol/min/kPa 4.58 (3.78; 6.92)
DLCO, % predicted 58 (47; 77)
V′O2 max, L/min 1.24 (1.04; 1.46)
V′O2 max, % predicted 67 (54; 78)
V′O2 max, mL/min/kg 16.95 (14.55; 19.95)
Comorbidities
Arterial hypertension 13 (42)
Coronary heart disease 4 (13)
Diabetes 2 (6)
Medications
Inhaled β-adrenergics 23 (74)
Inhaled anticholinergics 25 (81)
Inhaled corticosteroids 17 (55)
ACE inhibitor 5 (16)
Beta-blocker 7 (23)
Values are numbers of patients (% of group) or medians (lower quartile; upper quartile). RV, residual volume; 
FRC, functional residual capacity; DLCO, diffusing capacity.
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With ascent from 490 to 2,590 m, there was a signifi-
cant reduction in exercise endurance time from a median 
(quartiles) of 500 s (256; 795) at 490 m to 205 s (139; 297) 
at 2,590 m, i.e., there was a median difference (95% CI) of 
–303 s (–420 to –150) corresponding to a mean relative 
change of –54% (–67 to –40) (p < 0.001) (Fig. 2). The nu-
merical results are listed in Table 2, and a synopsis of the 
physiologic responses is provided in Figure 3.
Compared to 490 m, resting PaO2, SaO2, and PaCO2 
were reduced at 2,590 m in association with an increased 
V′E, breath rate, and ventilatory equivalents for oxygen 
uptake (V′E/V′O2) and carbon dioxide output (V′E/
V′CO2) (Table 2; Fig. 3). Resting and end exercise CTO 
were also reduced at 2,590 m compared to 490 m, but the 
differences in MCAv and in MTO between the values at 
490 m and those at 2,590 m, respectively, were not statis-
tically significant (Fig. 3b, c).
During the final 30 s of end exercise at 2,590 m, V′CO2 
and, to a greater extent, V′O2 were lower than the corre-
sponding values at 490 m, so that the respiratory exchange 
ratio was increased at 2,590 m. At end exercise, V′E, 
breath rates, and ventilatory equivalents were all elevated 
at 2,590 compared to 490 m (Table 2; Fig. 3). The adjust-
ed ventilatory equivalents accounting for the lower PB  
at 2,590 m were still slightly elevated over the values at 
490 m with the exception of V′E/V′CO2 at end exercise 
(Table 2).
Breathing reserve, computed as 40 × FEV1 – V′E, was 
reduced more at 2,590 m than at 490 m. The EELVs in-
creased significantly from rest to end exercise to a similar 
degree at both altitudes. The operational lung volumes 
(IRV and EILV) at end exercise were also similar at both 
altitudes (Tables 2, 3).
Pulse oximetry revealed a significant fall in SpO2 at rest 
and during exercise at 2,590 versus 490 m, and the exer-
cise-induced drop in SpO2 was more pronounced at 2,590 
m (Table 2; Fig.  3a). The arterial blood gas analysis at 
2,590 m revealed a considerable exercise-induced fall in 
PaO2 and SaO2 from the resting values, and the PaCO2 at 
end exercise at 2,590 m was also reduced compared to the 
resting values. Calculation of the death space fraction 
(VD/VT = [PaCO2 – PetCO2]/PaCO2) revealed a reduction 
with exercise at both altitudes.
The heart rate and mean blood pressure at end exercise 
were similar at both altitudes. Despite a more pronounced 
exercise-induced arterial hypoxemia, a similar increase in 
MCAv was observed at both altitudes (Fig. 3e). The cere-
bral blood flow response to exercise-induced arterial hy-
poxemia, expressed as change in MCAv per change in 
SpO2, was therefore lower at 2,590 m than at 490 m (Table 
2; Fig. 3). CTO remained stable over the course of exercise 
at 490 m, but it decreased at 2,590 m to end exercise values 
lower than those at 490 m (Fig. 3b). MTO decreased with 
exercise at both altitudes (Fig. 3c).
Comparison of the values recorded at end exercise at 
2,590 m with the corresponding values at isotime at 490 
m revealed that the patients had a lower V′O2 but a high-
er V′E, respiratory exchange ratio, and heart rate at 2,590 
m than at 490 m, and that they were more hypoxemic and 
had lower CTO and MTO at 2,590 m than at 490 m (Table 
0
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Fig. 2. Relative changes in endurance as-
sessed by constant-load bicycle exercise in 
patients with COPD at 2,590 m compared 
to the baseline value at 490 m. Individual 
changes and the median change (horizon-
tal line; reduction by 54%) are shown in 
percent of the baseline value at 490 m.
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3). The Borg CR10 Scale dyspnea but not leg fatigue rat-
ings at end exercise were increased at 2,590 versus 490 m.
Multivariate regression analysis with endurance at 
2,590 m as the (log-transformed) dependent variable re-
vealed that altitude (coefficient [95% CI] –0.452 [–0.558 
to –0.347]; p < 0.001), baseline endurance (coefficient 
0.0007 [0.0005–0.0008]; p < 0.001), and baseline FEV1 % 
predicted (coefficient 0.014 [0.006–0.022]; p = 0.001) 
were significant independent predictors, whereas the or-
der of altitude exposure (coefficient 0.083 [–0.019 to 
Table 2. Performance and physiologic response to exercise at 490 and 2,590 m
490 m 2,590 m
rest end exercise rest end exercise
Endurance, s NA 500 (256; 795) NA 205 (139; 297)*
V′O2, L/min 0.25 (0.20; 0.30) 1.01 (0.82; 1.23)* 0.26 (0.19; 0.33) 0.89 (0.64; 1.08)*, ¶
V′O2, % predicted V′O2 max 15 (12; 16) 62 (50; 72)* 14 (12; 16) 50 (40; 61)*, ¶
V′CO2, L/min 0.22 (0.16; 0.24) 0.91 (0.69; 1.13)* 0.21 (0.15; 0.26) 0.88 (0.64; 1.07)*, ¶
Respiratory exchange ratio 0.80 (0.75; 0.84) 0.90 (0.84; 0.94)* 0.80 (0.75; 0.84 0.99 (0.90; 1.06)*, ¶
V′E, L/min 12.2 (10.2; 14.1) 40.6 (35.5; 47.8)* 13.7 (12.4; 15.6)¶ 47.2 (39.6; 58.7)*, ¶
Tidal volume, L 0.7 (0.5; 0.9) 1.2 (1.1; 1.7)* 0.7 (0.6; 0.9) 1.3 (1.1; 1.6)*
Breathing rate, n/min 20 (18; 23) 35 (31; 37)* 21 (18; 28)¶ 36 (31; 42)*, ¶
Breathing reserve, L/min 55.4 (38.1; 76.1) 23.2 (11.9; 37.8)* 54.4 (37.7; 73.7) 17.6 (8.2; 26.5)*, ¶
Change in EELV, L 0 0.28 (0.06; 0.50)* 0 0.26 (0.05; 0.47)*
IRV, L 1.66 (1.10; 1.89) 0.95 (0.45; 1.24)* 1.52 (1.10; 1.83) 0.84 (0.63; 1.17)*
IRV/predicted TLC 0.15 (0.05; 0.26) 0.05 (–0.08; 0.16)* 0.12 (–0.01; 0.28) 0.02 (–0.11; 0.15)*
EILV/TLC 0.78 (0.72; 0.81) 0.86 (0.82; 0.92)* 0.78 (0.70; 0.82) 0.86 (0.82; 0.91)*
EILV/predicted TLC 0.85 (0.74; 0.95) 0.95 (0.84; 1.08)* 0.88 (0.72; 1.01) 0.98 (0.85; 1.11)*
V′E/V′O2 37.5 (31.7; 42.2) 37.2 (30.7; 42.6) 42.6 (37.5; 53.0)¶ 49.2 (42.1; 57.1)*, ¶
V′E/V′O2 adj. to PB at 490 m NA NA 40.1 (35.9; 53.3)¶ 41.2 (35.6; 49.3)¶
V′E/V′CO2 46.9 (40.0; 50.9) 40.7 (34.2; 46.5)* 52.4 (49.2; 63.3)¶ 49.7 (45.5; 55.5)*, ¶
V′E/V′CO2 adj. to PB at 490 m NA NA 50.3 (44.7; 65.4)¶ 42.4 (38.1; 47.4)
PetCO2, kPa 3.8 (3.5; 4.0) 4.6 (4.0; 4.9)* 2.9 (2.2; 3.4)¶ 3.3 (2.9; 3.5)*, ¶
VD/VT 0.33 (0.25; 0.36) 0.22 (0.11; 0.32)* 0.44 (0.30; 0.51)¶ 0.27 (0.22; 0.37)*, ¶
SpO2, % 95 (94; 96) 92 (89; 94)* 90 (86; 91)¶ 81 (77; 84)*, ¶
Arterial pH 7.42 (7.40; 7.44) 7.38 (7.35; 7.41)* 7.45 (7.43; 7.46)¶ 7.42 (7.39; 7.45)*, ¶
PaCO2, kPa 5.6 (5.0; 6.0) 5.6 (5.5; 5.8) 5.0 (4.6; 5.2)¶ 4.7 (4.3; 5.1)*, ¶
PaO2, kPa 9.0 (8.4; 9.4) 8.3 (6.8; 8.7) 6.7 (6.3; 7.4)¶ 5.8 (5.5; 6.5)*, ¶
SaO2, % 94 (92; 95) 93 (92; 94) 85 (82; 89)¶ 80 (75; 83)*, ¶
DAaPO2, kPa 5.6 (5.0; 6.8) 6.8 (5.7; 7.5) 3.0 (2.4; 3.4)¶ 3.7 (2.8; 4.2)*, ¶
Heart rate, n/min 78 (72; 83) 122 (108; 130)* 81 (74; 91) 122 (107; 128)*
Heart rate reserve, n/min 78 (70; 85) 33 (24; 46)* 75 (62; 82) 34 (25; 47)*
Mean arterial BP, mm Hg 108 (99; 116) 138 (119; 157)* 113 (99; 120) 147 (126; 155)*
CTO, % 62 (59; 67) 62 (56; 66) 59 (55; 61)¶ 55 (50; 60)*, ¶
MTO, % 68 (64; 71) 59 (53; 64)* 66 (64; 72) 53 (49; 64)*
MCAv, cm/s 47 (41; 56) 59 (51; 67)* 51 (45; 55) 62 (55; 67)*
MCAv response to hypoxia, %/% NA 6 (3; 12) NA 3 (2; 5)¶
Borg CR10 Scale score – dyspnea 0.5 (0; 1) 5 (4; 7)* 0 (0; 1) 7 (5; 8)*, ¶
Borg CR10 Scale score – leg fatigue 0 (0; 0.5) 4 (3; 6)* 0 (0; 1) 4 (2; 5)*
Total n = 31. Values are presented as medians (quartiles). Arterial blood gases were available at rest and during exercise for 31 and 
10 patients at 490 m, respectively, and for all patients at 2,590 m. * p < 0.05 vs. rest at the corresponding altitude; ¶ p < 0.05 vs. the cor-
responding value at 490 m at rest or end exercise, respectively. V′E, minute ventilation; V′O2, oxygen uptake; V′CO2, carbon dioxide out-
put; VD/VT, dead space to tidal volume ration calculated as VD/VT = [(PaCO2 – PetCO2)/PaCO2] [12]; PetCO2, end-tidal CO2 partial pres-
sure; SpO2 SaO2, arterial oxygen saturation by pulse oximetry and by co-oximetry, respectively; EELV, end-expiratory lung volume; 
DAaPO2, alveolar-arterial PO2 difference [28]; BP, blood pressure; MCAv, middle cerebral artery peak blood flow velocity; CTO, cerebral 
tissue oxygenation; MTO, muscle tissue oxygenation; MCAv response to hypoxia, % change in MCAv divided by corresponding % 
change in SpO2; breathing reserve, computed as 40 × FEV1 – V′E at end exercise; V′E/V′CO2 adj. and V′E/V′O2 adj. to PB at 490 m, ad-
justed values that account for changes in barometric pressure of values expressed in BTPS (see Methods for explanation); IRV, inspira-
tory reserve volume; EILV, end-inspiratory lung volume.
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0.184]; p = 0.112), baseline SpO2 (coefficient –0.014 
[–0.074 to 0.045]; p = 0.633), and lung diffusing capacity 
(coefficient –0.409 [–1.062 to 0.245]; p = 0.220) were not 
(R2 = 0.7603; p < 0.0001).
Discussion
The main finding of the current randomized trial on 
lowlanders with moderate-to-severe COPD (GOLD 
grades 2–3) was a major reduction in endurance by 54% 
during constant-load bicycle exercise at 2,590 m com-
pared to baseline values at 490 m. The performance dec-
rements at 2,590 m were associated with arterial hypox-
emia, deoxygenation of muscle and cerebral tissues, and 
an impaired cerebral blood flow response to the exercise-
induced decline in SpO2. The breathing reserve was re-
duced more at 2,590 m than at 490 m, with associated 
higher ventilatory equivalents for V′CO2 and V′O2 and a 
similar degree of dynamic hyperinflation. Therefore, the 
greater degree of dyspnea and impairment in exercise 
performance that lowlanders with COPD experience at 
moderate altitude is multifactorial, likely involving im-
pairments in systemic and cerebral availability of oxygen 
as well as in pulmonary gas exchange.
In 51 healthy young men ascending from 490 to 2,590 
m within a few hours, we previously observed a decrease 
in resting SpO2 from 95 to 91% associated with a decrease 
Table 3. Physiologic response to exercise at 490 and 2,590 m at isotimes
490 m 2,590 m
Endurance, s 205 (139; 297) 205 (139; 297)
V′O2, L/min 0.93 (0.78; 1.14)* 0.90 (0.64; 1.08)*, ¶
V′O2, % predicted V′O2 max 56 (48; 68)* 50 (41; 61)*, ¶
V′CO2, L/min 0.83 (0.65; 1.06)* 0.88 (0.64; 1.07)*
Respiratory exchange ratio 0.91 (0.84; 0.93)* 0.99 (0.90; 1.06)*, ¶
V′E, L/min 34 (31; 43)* 47.5 (39.6; 58.7)*, ¶
Tidal volume, L 1.3 (1.1; 1.8) 1.4 (1.1; 1.8)*
Breathing rate, n/min 28 (23; 32)* 36 (31; 42)*, ¶
Breathing reserve, L/min 28.0 (17.2; 49.0)* 18.7 (8.3; 35.2)*, ¶
Change in EELV, L 0.27 (0.13; 0.49) 0.12 (0.00; 0.63)
IRV, L 0.81 (0.34; 1.18)* 0.84 (0.62; 1.17)*
IRV/predicted TLC 0.05 (–0.09; 0.16)* –0.01 (–0.13; 0.15)*
EILV/TLC 0.87 (0.83; 0.94)* 0.86 (0.82; 0.91)*
EILV/predicted TLC 0.95 (0.84; 1.09)* 1.01 (0.85; 1.13)*
V′E/V′O2 36 (29; 40) 49 (42; 57)*, ¶
V′E/V′O2 adj. to PB at 490 m NA 41 (36; 49)
V′E/V′CO2 40 (34; 43)* 50 (45; 55)*, ¶
V′E/V′CO2 adj. to PB at 490 m NA 42 (38; 47)*
SpO2, % 93 (89; 95)* 81 (77; 84)*, ¶
Heart rate, n/min 109 (103; 119)* 122 (107; 128)*, ¶
Heart rate reserve, n/min 47 (32; 54)* 35 (25; 47)*, ¶
Mean arterial BP, mm Hg 136 (126; 148)* 149 (126; 158)*, ¶
CTO, % 62 (57; 65) 55 (50; 60)*, ¶
MTO, % 58 (53; 65)* 53 (48; 64)*, ¶
MCAv, cm/s 59 (52; 70)* 62 (52; 67)*
MCAv response to hypoxia, %/% 3 (1; 7) 2 (1; 2)
Isotime refers to the time of end exercise in the test with the shorter endurance. In 29 of 31 instances, this was 
the test at 2,590 m (see Fig. 2). Values are presented as medians (quartiles). * p < 0.05 vs. rest at the correspond-
ing altitude; ¶ p < 0.05 vs. isotime at 490 m. V′O2, oxygen uptake; V′CO2, carbon dioxide output; SpO2, arterial 
oxygen saturation by pulse oximetry; EELV, end-expiratory lung volume; BP, blood pressure; MCAv, middle 
cerebral artery peak blood flow velocity; CTO, cerebral tissue oxygenation; MTO, muscle tissue oxygenation; 
MCAv response to hypoxia, % change in MCAv divided by corresponding % change in SpO2; breathing reserve, 
computed as 40 × FEV1 – V′E at end exercise; V′E/V′CO2 and V′E/V′O2 adj. to PB at 490 m, adjusted values that 
account for changes in barometric pressure in values expressed in BTPS (see Methods for explanation); IRV, in-
spiratory reserve volume; EILV, end-inspiratory lung volume.
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Fig. 3. Changes in physiologic variables from rest to end exercise 
at 490 m and 2,590 m shown as medians and interquartile ranges. 
a Pulse oximetry (SpO2). b Cerebral tissue oxygenation. c Muscle 
tissue oxygenation. d Heart rate. e Middle cerebral artery peak 
blood flow velocity (MCAv). f PaCO2. g Minute ventilation (V′E). 
h Ventilatory equivalent for oxygen (V′E/V′O2). i Ventilatory 
equivalent for carbon dioxide (V′E/V′CO2). * p < 0.05 vs. rest at 
corresponding altitude; ¶ p < 0.05 vs. corresponding value at 490 
m at rest or end exercise, respectively; # p < 0.05 for comparison of 
corresponding exercise-induced changes from rest to end exercise 
at 2,590 vs. 490 m.
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in end-tidal PCO2 (the surrogate of PaCO2) from 5.3 to 4.8 
kPa [24]. This was consistent with an increase in ventila-
tory drive, and thus alveolar ventilation, induced by the 
hypobaric hypoxia. Exercise tests were not performed in 
that study. Investigations in 8 elite cyclists at sea level and 
after 1 day of exposure to 2,340 m revealed a decrease in 
Wmax by 14%, in V′O2 max by 13%, and in maximal cy-
cling endurance by 26% at a constant load of 80% of the 
sea level Wmax [25]. Similar data on the physiologic effects 
of altitude on COPD patients have not been available. 
One uncontrolled case study on 18 COPD patients (mean 
FEV1 42% predicted) ascending within 2–3 h from sea 
level to 2,086 m revealed a reduction in 6-min walk dis-
tance within 1 h after arrival at 2,086 m by 52% in asso-
ciation with drops in SpO2 to 75% [26]. The participants 
in the current study had a slightly higher FEV1 (56% pre-
dicted) (Table 1) than those in the cited study, but they 
were exposed to a higher altitude of 2,590 m, which may 
explain the similar reduction in exercise endurance by 
54% of the value at 490 m. Differences in timing and type 
of exercise hamper further comparisons between the two 
studies. To our knowledge, the current randomized trial 
for the first time provides quantitative data on reductions 
in exercise performance and the underlying physiologic 
mechanisms in lowlanders with COPD travelling to mod-
erate altitude.
Our data recorded at low altitude (490 m) are consis-
tent with those of previous studies showing a reduced 
breathing reserve and exercise-induced hypoxemia in pa-
tients with severe COPD [27]. Although the breathing re-
serve of the patients in the current study was not exhaust-
ed at either of the two altitudes, it was reduced more at 
2,590 m than at 490 m (Table 2), most likely due to hy-
poxic ventilatory stimulation and because of the more 
pronounced ventilatory inefficiency for V′O2 and V′CO2 
at 2,590 m. The increases in ventilatory equivalents for 
V′CO2 and V′O2 were mainly due to the reduced PB, since 
increases in these variables after adjustment for changes 
in gas density at 2,590 m were minor. Thus, the effects of 
altitude-related changes in PaCO2 and alveolar PCO2 and 
of VD/VT on V′E/V′CO2 seemed to be small. The exercise-
induced increase in alveolar-arterial PO2 difference [28] 
at 2,590 m may have contributed to the increased V′E/
V′O2. Despite the higher V′E at end exercise at 2,590 m, 
dynamic hyperinflation was not greater than that at 490 
m, which is possibly related to the reduced air density and 
its effect on airflow resistance at the higher altitude [29], 
even though FEV1 and FEV1/FVC were similar at 2,590 
and 490 m. Consistently, IRV and EILV at end exercise 
were similar at both altitudes, suggesting that the higher 
V′E at 2,590 m was not associated with higher operation-
al lung volumes. Therefore, the impairment in exercise 
performance and excessive dyspnea in COPD patients 
travelling to high altitude were more likely due to a re-
duced oxygenation of the brain than to mechanical ven-
tilatory constraints. In terms of clinical implications, 
these findings may suggest that the reduced exercise 
endurance of COPD patients at higher altitudes might 
be alleviated by oxygen supplementation rather than 
by pharmacological bronchodilation.
The reduced inspiratory PO2 at 2,590 m exacerbated 
the hypoxemia at rest and during exercise, despite the hy-
poxic stimulation of V′E that was reflected in a lower 
PaCO2 at 2,590 m. In healthy subjects, cerebral deoxygen-
ation recorded by NIRS during exposure to a high simu-
lated altitude was associated with reduced exercise per-
formance [30]. These data and improvements in CTO 
and exercise performance with oxygen supplementation 
at high altitude suggest a role of cerebral hypoxia in exer-
cise limitation [31, 32]. In the current study on COPD 
patients, CTO remained stable throughout the exercise 
tests at 490 m. However, CTO dropped significantly at 
2,590 m (Table 1; Fig. 3). Moreover, the response of cere-
bral blood flow to hypoxemia was reduced, possibly re-
lated to hypocapnia-induced cerebral vasoconstriction at 
2,590 m [33]. Cerebral hypoxia may therefore have con-
tributed to exercise limitation in the COPD patients at 
2,590 m. In contrast to CTO, MTO was similar at end 
exercise at both altitudes, suggesting that impairment of 
MTO was not a main factor in the reduced performance 
at 2,590 m.
Heart rates at end exercise were similar at both alti-
tudes. Presumably, a further augmentation of the cardio-
vascular response to exercise at 2,590 m was prevented by 
premature termination of exercise due to pronounced 
dyspnea. Alternatively, hypoxemia may have restricted 
the maximal heart rate during exercise at 2,590 m, as ob-
served in some studies on healthy individuals acutely ex-
posed to hypoxia [34], although another report suggested 
that a decrease in maximal heart rate occurred only after 
several days of acclimatization at high altitude [35]. Hy-
pobaric hypoxia has been associated with elevation of 
pulmonary artery [2] and systemic blood pressures [36].
In terms of the clinical relevance of our findings, it is 
important to note that despite performing physical work 
to exhaustion, none of the patients with a severity grade 
of COPD (GOLD 2–3) that usually allows still being ac-
tive and considering travel experienced a serious adverse 
event. The selected study altitude of 2,590 m is of particu-
lar interest, because it is similar to altitudes visited during 
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recreational walking or skiing and not far off the maximal 
cruising altitude equivalent permitted in commercial air 
flights (8,000 ft or 2,438 m). The results are therefore re-
assuring for COPD patients considering travelling at 
moderately high altitudes or air travel.
Conclusions
In conclusion, our results demonstrate that COPD pa-
tients travelling to moderate altitudes experience a con-
siderable limitation of exercise performance that seems 
relevant to activities of daily life. The results of the com-
prehensive physiologic evaluation performed in the cur-
rent study are consistent with a reduced exercise perfor-
mance due to combined adverse effects of hypobaric hy-
poxia on dyspnea, pulmonary gas exchange, and cerebral 
hypoxia. These data may help to counsel patients with 
COPD planning high-altitude travelling.
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